Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-05-31
2011-05-31
Harris, Alana M (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100, C424S133100, C424S134100, C424S135100, C424S136100, C424S138100, C424S141100, C424S152100, C424S155100, C424S156100
Reexamination Certificate
active
07951917
ABSTRACT:
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 6515110 (2003-02-01), Whitlow et al.
patent: 7262028 (2007-08-01), Van Berkel et al.
patent: 314317 (1989-05-01), None
patent: WO 89/02922 (1989-04-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/06217 (1993-04-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 96/27011 (1996-09-01), None
patent: WO 96/37621 (1996-11-01), None
Hu, S. et al., Cancer Res. 56: 3055-3061, 1996.
de Kruif et al., The Journal of Biological Chemistry, 271(13): 7630-7634, 1996.
Greenwood, J. et al., Ther. Immunol., 1(5): 247-255, 1994.
Rudikoff et al. Proc Natl Acad Sci USA, vol. 79 pp. 1979-1983, 1982.
Bedzyk et al., “Active Site Structure and Antigen Binding Properties of Idiotypically Cross-reactive Anti-fluorescein Monoclonal Antibodies”,The Journal of Biological Chemistry, 265(1):133-138 (1990).
Bryunck, A. et al., “Characterisation of a humanized bispecific monoclongal antibody for cancer therapy”,Br. J. Cancer, 67:436-440 (1993).
Carter, P. et al., “Toward the Production of Bispecific Antibody Fragments for Clinical Applications”,J. Hematotherapy, 4(5):463-470 (Oct. 1995).
Carter, P. et al., “Engineering antibodies for imaging and therapy”,Curr. Opin. Biotechnology, 8(4):449-454 (Aug. 1997).
De Jonge, J. et al., “Production and Characterization of Bispecific Single-Chain Antibody Fragments”,Mol. Immunol., 32(17-18):1405-1412 (Dec. 1995).
Goddard et al., NCBI Genbank AF048774 (1998).
Goddard et al., NCBI Genbank AF048775 (1998).
Gulliver, G. et al., “Conversion of an Anti-single-stranded DNA Active Site to an Anti-fluorescein Active Site through Heavy Chain Complementarity Determining Region Transplantation”The Journal of Biological Chemistry, 269(11):7934-7940 (1994).
Gulliver, G. et al., “Effect of Transplantation of Antibody Heavy Chain Complementarity Determining Regions on Ligand Binding”,The Journal Biological Chemistry, 269(39):24040-24045 (Sep. 30, 1994).
Kriangkum, J. et al,. “Bispecific and bifunctional single chain recombinant antibodies”Biomolecular Engineering, 18(1):31-40 (Aug. 2001).
Mallender, W. et al., “Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20”,The Journal of Biological Chemistry, 271(10):5338-5346 (Mar. 8, 1996).
Mallender, W. et al., “Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Anibody”,The Journal of Biological Chemistry, 269(1):199-206 (Jan. 7, 1994).
Massino et al., “Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay”,Journal of Immunological Methods, 201:57-66 (1997).
Merchant et al., “An efficient route to human bispecific IgG”,Nature Biotechnology, 16:677-681 (Jul. 1998).
Muller, KM et al., “The first constant domain (CH1 and Cl) of an antibody used as heterodimerization domain for bispecific miniantibodies”,FEBS Letter, 422(2):259-264 (Jan. 30, 1998).
Muller, KM et al., “A dimeric bispecific miniantibody combines two specificities with avidity”,FEBS Letter, 432(1-2):45-49 (Jul. 31, 1998).
Pluckthun, A. et al., “New protein engineering approaches to multivalent and bispecific antibody fragments”,Immunotechnology, 3(2):83-105 (Jun. 1997).
Reddy, V. et al., “Production of Hybrids Secreting Bispecific Antibodies Recognising CEA and Doxorubicin”,Anticancer Research, 13:2077-2084 (1993).
Segal, DM et al., “Introduction: bispecific antibodies”,J. Immunol Methods, 248(1-2):1-6 (Feb. 1, 2001).
Smith et al., “Variable Region Primary Structures of Monoclonal Anti-DNA Autoantibodies from NZB/NZW F1Mice”,Molecular Immunology, 27(5):463-470 (1990).
Tomlinson, IM et al., “The structural repertoire of the human VKdomain”,EMBO Journal, 14(18):4628-4638 l (Sep. 15, 1995).
Tomlinson, I et al., “Methods for Generating Multivalent and Bispecific Antibody Fragments”,Methods Enzymol., 326:461-479 (2000).
Tso, JY et al., “Preparation of a Bispecific F(ab′)2Targeted to the Human IL-2 Receptor”,J. Hematotherapy, 4(5):389-394 (Oct. 1995).
Vuillez, J. et al., “Two-Step Immunoscintigraphy for Non-Small-Cell Lung Cancer Staging Using a Bispecific Anti-CEA/Anti-Indium-DTPA Antibody and an Indium-111-Labeled DTPA Dimer”,The Journal of Nuclear Medicine, 38(4)1507-511 (Apr. 1997).
Luo, D. et al., “V1-Linker-Vh Orientation-Dependent Expression of Single Chain Fv Containing an Engineered Disulfide-Stabilized Bond in the Framework Regions”,J. Biochem., 118:825-831 (1995).
Nieba, L. et al., “Disrupting the hydrophobic patches at the antibody variable/constant domain interace: improved in vivo folding and physical characterization of an engineered scFv fragment”,Protein Engineering, 10(4):435-444 (1997).
Reiter, Y. et al., “Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv”,Protein Engineering, 7(5):697-704 (1994).
Cox, et al., A Directory of Human Germ-line Vx Segments Reveals a Strong Bias in Their Usage Eur. J. Immunol., 1994, 24:827-836.
Williams et al., Cloning and Sequencing of Human Immunoglobulin V1 Gene Segments Eur. J. Immunol., 1993, 23:1456-1461.
Mariuzza RA, et al., The Structural Basis of Antigen-Antibody Recognition Annu. Rev. Biophys. Biophys. Chem. 1987; 16:139-59.
Giusti AM, et al., Somatic Diversification of S107 from an Antiphosphocholine to an Anti-DNA Autoantibody is Due to a Single Base Change in its Heavy Chain Variable Region Proc. Natl. Acad. Sci. USA. May 1987; 84(9):2926-2930.
Chien NC, et al., Significant Structural and Functional Change of an Antigen-Binding Site by a Distant Amino Acid Substitution: Proposal of a Structural Mechanism Proc. Natl. Acad. Sci. USA. Jul 1989; 86(14): 5532-6.
Caldas C, et al., Humanization of the Anti-CD18 Antibody 6.7: an Unexpected Effect of a Framework Residue in Binding to Antigen Mol. Immol. May 2003; 39 (15): 941-952.
Barton, “Protein sequence alignment and database scanning”, Protein Structure Prediction, pp. 31-63 (1996).
Eck et al., “Gene-Based Therapy”,In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, Chap. 5, pp. 77-101 (1996).
George et al., “Current Methods in Sequence Comparison and Analysis”,Macromolecular Sequencing and Synthesis, pp. 127-149 (1988).
Houdebin
Arathoon W. Robert
Carter Paul J.
Merchant Anne M.
Presta Leonard G.
Genentech Inc.
Harris Alana M
Holleran Anne L
Jones Day
LandOfFree
Method for making multispecific antibodies having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for making multispecific antibodies having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for making multispecific antibodies having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653829